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Recurrent Pseudomonas aeruginosa infections coupled with robust,
damaging neutrophilic inflammation characterize the chronic lung dis-
ease cystic fibrosis (CF). The proresolving lipid mediator, 15-epi lipoxin
A4 (15-epi LXA4), plays a critical role in limiting neutrophil activation
and tissue inflammation, thus promoting the return to tissue homeo-
stasis. Here, we show that a secreted P. aeruginosa epoxide hydrolase,
cystic fibrosis transmembrane conductance regulator inhibitory factor
(Cif), can disrupt 15-epi LXA4 transcellular biosynthesis and function. In
the airway, 15-epi LXA4 production is stimulated by the epithelial-
derived eicosanoid 14,15-epoxyeicosatrienoic acid (14,15-EET). Cif sab-
otages the production of 15-epi LXA4 by rapidly hydrolyzing 14,15-EET
into its cognate diol, eliminating a proresolving signal that potently
suppresses IL-8–driven neutrophil transepithelial migration in vitro.
Retrospective analyses of samples from patients with CF supported
the translational relevance of these preclinical findings. Elevated levels
of Cif in bronchoalveolar lavage fluid were correlated with lower
levels of 15-epi LXA4, increased IL-8 concentrations, and impaired lung
function. Together, these findings provide structural, biochemical, and
immunological evidence that the bacterial epoxide hydrolase Cif dis-
rupts resolution pathways during bacterial lung infections. The data
also suggest that Cif contributes to sustained pulmonary inflammation
and associated loss of lung function in patients with CF.
Pseudomonas aeruginosa | epoxide hydrolase | inflammation | lipoxin |
cystic fibrosis
Chronic pulmonary inflammation and persistent bacterial in-fections are pathological hallmarks of the genetic disease
cystic fibrosis (CF) (1). CF is caused by mutations that impair the
function of the cystic fibrosis transmembrane conductance regulator
(CFTR), an ion channel that controls epithelial fluid and ion ho-
meostasis. The resulting failure of mucociliary clearance in the CF
lung allows microorganisms to repeatedly infect the respiratory tract
(2). These bacterial infections incite robust inflammatory responses,
dominated by elevated proinflammatory cytokines and continued
accumulation of neutrophils in the CF airway (1). However, these
responses are ineffective at clearing pathogenic microbes in the CF
lung (3), instead creating a hyperinflammatory cycle that leads to
host tissue damage, respiratory failure, transplant, or death.
Most airways of adult patients with CF are chronically infected
by the opportunistic bacterial pathogen Pseudomonas aeruginosa,
which is a major cause of morbidity and mortality. P. aeruginosa
thrives in the hyperinflammatory CF lung, forming biofilms that are
mechanically robust and resistant to clinically achievable levels of
antibiotics (2). P. aeruginosa also persists in the airways by interfering
with host defense via secreted bacterial virulence factors and small
molecules (2). We recently showed that P. aeruginosa secretes the
CFTR inhibitory factor (Cif), an epoxide hydrolase that triggers the
degradation of ABC transporter family members, including CFTR
(4–8). Cif transcripts have been observed in sputum from patients
with CF, and longitudinal studies of clinical isolates from individual
patients confirm that P. aeruginosamaintains Cif expression for up to
15 y (7, 9). Nonetheless, Cif’s role in CF pathogenesis and the
identity of possible host epoxide substrates have remained unclear.
Following a pathogenic insult, the host rapidly releases polyun-
saturated fatty acids from cell membranes and converts them into
various lipid mediators that either stimulate or inhibit inflammation.
The correct balance of these signals is required to optimize clearance
while minimizing collateral damage to host tissues, and perturba-
tions in either direction can be deleterious (10). Among these lipid
mediators, arachidonic acid-derived eicosanoids, including epox-
ides, play important roles. Although many eicosanoids induce
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proinflammatory cascades, recent studies have also identified im-
munomodulatory and proresolving functions (11, 12). In particular,
lipoxins decrease neutrophil extravasation and enhance macro-
phage efferocytosis, thus promoting the resolution of inflammation
and a return to tissue homeostasis (13, 14). In the CF lung, the
concentration of lipoxin A4 (LXA4) is significantly reduced, sug-
gesting that a failure to activate proresolving mechanisms con-
tributes to excessive inflammation in the airway (15). In this study,
we show that Cif selectively converted an endogenous epoxide-
containing eicosanoid 14,15-epoxyeicosatrienoic acid (14,15-EET)
to its corresponding diol, destroying the signal that triggers in-
creased biosynthesis of the specialized proresolving mediator 15-epi
LXA4. The translational relevance of this unexpected biochemical
virulence activity to clinical CF was investigated by retrospective
analysis of bronchoalveolar lavage fluid (BALF) samples and sug-
gested that Cif contributes to the hyperinflammatory environment of
the chronically infected CF lung.
Results
Cif Specifically Hydrolyzed the Mammalian Epoxyeicosatrienoic Acid
14,15-EET.Airway epithelial cells (AECs) produce numerous lipid
mediators. Via a major cytochrome P450 monooxygenase-catalyzed
pathway, they convert arachidonic acid into epoxide-containing
eicosanoids called EETs (Fig. S1A) (10). To assess the ability of
Cif to hydrolyze these candidate epoxide substrates, we incubated
the enzyme with each of the four mammalian EET regioisomers,
5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET, and assayed for
production of a vicinal diol through a colorimetric assay (5). Cif
hydrolyzed 14,15-EET, but did not exhibit detectable epoxide
hydrolase activity for any of the other three regioisomers (Fig. 1A),
suggesting selective conversion of 14,15-EET by Cif to the corre-
sponding vicinal diol 14,15-dihydroxyeicosatrienoic acid (DHET)
(Fig. 1B). An immunoassay selective for the diol product con-
firmed conversion of 14,15-EET to 14,15-DHET by Cif, but not by
the structurally conserved mutant Cif-D129S (Fig. S1B), which is
enzymatically inactive (16).
Previous crystal structures show a limited steric volume for the Cif
active site (5), and almost all previously reported Cif substrates are
terminal epoxides, which can enter deep into the active site. In
contrast, lipid mediators typically carry epoxide groups in the middle
of an extended carbon chain and were thus thought unlikely to serve
as Cif substrates. To investigate how the enzyme catalyzes 14,15-EET
hydrolysis, we incubated the compound with the Cif-E153Q mutant,
which can attack substrates with its active-site nucleophile, but cannot
catalyze the secondary attack required for product release (17). We
then crystallized the resulting complex for X-ray diffraction analysis.
The refined structure (Table S1) showed the expected adduct of the
catalytic Asp129 (D129) nucleophile with the 20-carbon EET chain
attached at the C15 moiety (Fig. 1C and Fig. S2). Unexpectedly, it
also showed that the active site could expand at both ends, opening a
tunnel through the enzyme to accommodate the extended eicosanoid
substrate (Fig. 1D). The strong preference for 14,15-EET presumably
reflects the shorter distance in the other regioisomers between the
epoxide moiety and the terminal carboxylate, which would thus have
to be unfavorably sequestered within the active site during hydrolysis.
P. aeruginosa Can Trigger Hydrolysis of Epithelial 14,15-EET Produced
in Response to Inflammation. To determine whether Cif’s regio-
selectivity matches the biological epoxides present in the airway, we
first tested whether polarized immortalized CF AECs (CFBE41o-,
hereafter called CFBE cells) produce 14,15-EET in response to
inflammatory signals. We treated CFBE cells with tumor necrosis
factor-α (TNFα) (18) and performed lipid extractions on apical
supernatants. Eicosanoid levels were determined in parallel by im-
munoassay (Fig. 2) and by mass spectrometry (Fig. S3A). Super-
natants from CFBE cells exposed to TNFα showed a substantial
increase in 14,15-EET levels, compared with untreated cells (Fig.
2A and Fig. S3A).
Furthermore, when CFBE cells were exposed to TNFα in the
presence of purified Cif-WT protein, the apical level of 14,15-EET
was reduced to that of unstimulated controls, whereas the catalyt-
ically inactive Cif-D129S protein had no significant impact on
14,15-EET levels (Fig. 2A). We next sought to determine whether
P. aeruginosa could use Cif activity to hydrolyze CFBE-derived
14,15-EET. We first showed that presence of 14,15-EET did not
affect the growth rate of P. aeruginosa strain PA14, which expresses
Cif (Fig. S4). CFBE cells were treated with TNFα and exposed to
strain PA14 or to the corresponding cif deletion strain PA14Δcif
(7). Apical supernatant concentrations of 14,15-EET were signifi-
cantly reduced in the presence of the Cif-producing strain PA14,
compared with the TNFα-only control (Fig. 2B). Similar results
were observed for well-differentiated primary CF human bronchial
epithelial cells (CF HBEs) (Fig. 2C) and also for the non-CF Calu3
cell line (Fig. S3B). In each case, PA14Δcif had no statistically
significant effect on the 14,15-EET levels. The Cif effect is not
associated with differences in overall P. aeruginosa CF AEC cyto-
toxicity. Both PA14 and PA14Δcif showed minimal cytotoxicity at
the 5-h time point used in our experiments (Fig. S3C). Interestingly,
we detected comparable levels of 14,15-EET secreted by CF and
non-CF AECs following TNFα treatment, suggesting that both CF
and non-CF epithelial cells were similarly capable of secreting
14,15-EET in response to an inflammatory stimulus. Taken to-
gether, our data demonstrate that Cif enables P. aeruginosa to
promote the hydrolysis of 14,15-EET secreted by AECs and that
Cif is necessary for efficient hydrolysis.
Cif-Mediated 14,15-EET Hydrolysis Reduced 15-epi LXA4 Production
and Disinhibited Transepithelial Migration. AEC-derived 14,15-EET
acts as a transcellular signal and stimulates neutrophil generation
of the proresolving mediator 15-epi LXA4, whereas other EET
regioisomers do not (18, 19). Thus, we next examined whether












































Fig. 1. The P. aeruginosa enzyme Cif hydrolyzes the epoxyeicosatrienoic acid
14,15-EET. (A) Incubation of recombinant Cif with each of the EET regioisomers
demonstrates its ability to selectively hydrolyze 14,15-EET (black bars). ****P <
0.0001 for 14,15-EET compared with all other experimental conditions, one-way
ANOVA with Tukey’s post hoc test; n ≥ 3; mean ± SD. (B) Cif hydrolyzes the ep-
oxide moiety of 14,15-EET, converting it to the vicinal diol 14,15-DHET. (C) Ex-
perimental electron density (2mFO-DFC; blue mesh, contoured at 1σ) shows the
refined position of the covalent enzyme–substrate intermediate formed by nu-
cleophilic attack of Asp129 (D129; blue carbons; chain D) on 14,15-EET (yellow
carbons). (D) In the covalently linked structure, several residues shift, opening a
tunnel through the active site (blue surface area representation), allowing for
accommodation of the 14,15-EET (yellow carbons) adduct. The active site of the
apo enzyme (PDB ID 3KD2) does not contain this tunnel. Its boundaries are shown
as red dotted lines. Noncarbon atoms are colored by atom type (N, blue; O, red).









biosynthesis of 15-epi LXA4. Neutrophils obtained from healthy
donors or subjects with CF were exposed to 14,15-EET alone or in
combination with either Cif-WT or Cif-D129S. Following incu-
bation, lipids were extracted from supernatants and quantified by
ELISA for 15-epi LXA4. As expected, neutrophils generated 15-epi
LXA4 when incubated with 14,15-EET, and 15-epi LXA4 levels were
significantly reduced in the presence of Cif-WT (Fig. 3A). Similar
results were observed for neutrophils from donors with CF (Fig.
S5B). In a neutrophil–CFBE coculture model, CFBE cells were
treated with TNFα to induce the production of 14,15-EET and then
incubated with neutrophils. Apical supernatants from the neutro-
phil–CFBE coculture showed robust production of 15-epi LXA4
following TNFα stimulation. The addition of Cif to the neutrophil–
CFBE coculture substantially reduced transcellular generation of
15-epi LXA4 to near baseline levels (Fig. 3B). The 15-epi LXA4 is the
15(R) epimer of LXA4, yet these epimers have distinct biosynthetic
pathways (11). As a control, we also used the coculture system to
assess transcellular generation of LXA4. As expected, Cif had no
significant effect on LXA4 levels (Fig. S5A), but instead appeared
to be specific for the 15-epi LXA4 biosynthetic pathway.
The 15-epi LXA4 is a potent inhibitor of neutrophil trans-
epithelial migration (14), so we next modified our coculture system
to examine whether Cif affects neutrophil transepithelial migration.
Polarized CFBE cell monolayers were grown on the bottom of
Transwell permeable membrane supports to physiologically model
neutrophil transepithelial migration in the basolateral-to-apical di-
rection. The neutrophil chemoattractant IL-8 was added in the
apical compartment to drive neutrophil migration (20). Exposure of
neutrophils to 14,15-EET (100 nM, 45 min) or to 15-epi LXA4
(100 nM, 15 min) significantly decreased transepithelial migration
by 74% and 84%, respectively (Fig. 3C). Cif-WT, but not Cif-D129S,
significantly abrogated the inhibition of neutrophil transepithelial
Fig. 2. Cif hydrolyzes 14,15-EET derived from CF AECs. (A–C) Treatment of polarized CF AECs with TNFα (1 ng/mL) for 24 h stimulates increased apical secretion of 14,15-
EET (blue bars or symbols) compared with untreated cells (black bars or symbols). (A) Recombinant Cif protein hydrolyzes 14,15-EET produced by TNFα-treated CFBE cells.
CFBE cells were apically treated with either recombinant Cif-WT or Cif-D129S (1 μM) for 45 min (red or gray bars, respectively). Apical secretions were collected in cold
MeOH, solid-phase lipid extracted, and analyzed for 14,15-EET concentrations by ELISA. ***P < 0.001; one-way ANOVA with Tukey’s post hoc test; n ≥ 3; mean ± SD.
(B) Cif secreted by P. aeruginosa hydrolyzes 14,15-EET produced by TNFα-treated CFBE cells. CFBE cells were inoculated apically with either PA14 or deletion mutant
PA14Δcif (MOI= 25) for 5 h (red bars and gray bars, respectively) and analyzed for 14,15-EET concentrations by ELISA. ***P < 0.001 and ****P < 0.0001; one-way ANOVA
with Tukey’s post hoc test; n≥ 3;mean± SD. (C) P. aeruginosa hydrolyzes 14,15-EET produced by primary CF airway epithelial cells. Primary CF HBEs were apically exposed
to either PA14 or deletion mutant PA14Δcif (MOI = 25) for 5 h (red and gray symbols). Apical secretions were collected and analyzed for 14,15-EET concentrations by
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Fig. 3. Cif-mediated 14,15-EET hydrolysis suppresses neutrophil-derived 15-epi LXA4 and restores neutrophil transepithelial migration. (A) Neutrophil generation of
15-epi LXA4 in the presence of 14,15-EET (blue symbols) is reduced in the presence of recombinant Cif-WT (red symbols) but not by the catalytic mutant Cif-D129S
(gray symbols). Freshly isolated human neutrophils from healthy donors (106) were incubated with 14,15-EET (1 μM) in the presence of either Cif-WT (1 μM) or
Cif-D129S (1 μM). The reactions were stopped with cold MeOH, lipid extracted, and analyzed for 15-epi LXA4 concentrations by ELISA. *P < 0.05, **P < 0.01; one-way
ANOVA with Tukey’s post hoc test; n ≥ 3; mean. (B) Cif hydrolysis of 14,15-EET suppresses the production of 15-epi LXA4 in CFBE–neutrophil coculture. Polarized
CFBEs stimulated with TNFα (1 ng/mL) for 24 h (blue bar) were treated apically with Cif-WT (1 μM) for 45 min (red bar), before the apical addition of 1.5 × 106 of
freshly isolated neutrophils for an additional 15 min. The apical supernatants from the cocultures were collected and analyzed for 15-epi LXA4 by ELISA. Data are
normalized to CFBEs treated with TNFα. *P < 0.05, **P < 0.01; one-way ANOVA with Tukey’s post hoc test; n ≥ 3; mean ± SD. (C) Cif hydrolysis of 14,15-EET
abrogates the reduction of neutrophil transepithelial migration mediated by 15-epi LXA4. Freshly isolated human neutrophils (5 × 10
5) were calcein-AM loaded and
treated either with 15-epi LXA4 alone (light blue bar) or in the presence of Cif-WT (light red bar) or with 14,15-EET alone (blue bar) or in the presence of Cif-WT (red
bar) or Cif-D129S (gray bar) for 15–45 min, as noted in Materials and Methods. The treated neutrophils were applied to the basolateral side of polarized CFBEs
following the apical addition of the chemoattractant IL-8 (black bar, IL-8 positive control; white bar, no IL-8 negative control). After 2 h, calcein-AM fluorescencewas
measured in the apical compartment to assess neutrophil transepithelial migration. Results are shown for the comparison of each experimental condition to the
migration measured in the IL-8 positive control condition. ****P < 0.0001; n.s., not significant; one-way ANOVA with Tukey’s post hoc test; n ≥ 4; mean ± SD.
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migration mediated by the addition of 14,15-EET (Fig. 3C). How-
ever, Cif-WT had no effect on migration when added in the pres-
ence of 15-epi LXA4, consistent with our proposal that its inhibitory
effect on 15-epi LXA4 is not direct, but instead mediated by hy-
drolysis of 14,15-EET. These data demonstrate that Cif can disrupt
15-epi LXA4 regulation of neutrophil transepithelial migration in
the presence of IL-8.
Cif Expression in Patients with CF Is Widespread and Correlates with
Elevated IL-8, Loss of 15-epi LXA4, and Reduced Pulmonary Function.
To assess the extent of patient exposure to Cif, we tested serum
samples from a collection of adult donors with CF and donors
without CF for the presence of Cif-specific antibodies by ELISA
(Table S2 and Fig. 4A). Patients with CF uniformly exhibited high
levels of α-Cif antibodies, suggesting widespread exposure to Cif
protein during the natural history of disease. Based on our in vitro
preclinical data (Figs. 1–3), we hypothesized that Cif levels in pa-
tients with CF would be positively correlated with lung inflammation
and inversely correlated with BALF levels of 15-epi LXA4 and with
several measures of lung function. To test these hypotheses, we
obtained BALF from a random cross-sectional cohort of pediatric
subjects with CF who had undergone bronchoscopy (Table S3).
Using newly developed Cif-specific antisera (Fig. S6), we quantified
Cif abundance in BALF samples that tested positive for the pres-
ence of P. aeruginosa lipopolysaccharide. We also quantified the
levels of IL-8 and 15-epi LXA4 in these samples by ELISA. A
Pearson cross-correlation matrix of available data demonstrated
patterns clearly consistent with our predictions (Fig. 4B). Pulmonary
function tests (Fig. 4B, solid outline) showed strong positive corre-
lations with each other, consistent with CF airway disease. The 15-
epi LXA4 levels positively correlated with lung function (Fig. 4B,
dashed outline), consistent with the idea that proresolution signals
are protective against inflammatory lung damage in CF. As pre-
dicted, Cif inversely correlated with both 15-epi LXA4 and pulmo-
nary function measures (Fig. 4B, dotted outline), and IL-8
correlated inversely with 15-epi LXA4 and positively with Cif (Fig.
4B, red line). To investigate these patterns in more detail, we divided
patients into “Cif low” and “Cif high” groups (Fig. 4C), using 10 ng
Cif per milligram of total protein to delineate groups. Individual
analyses confirmed significantly reduced levels of 15-epi LXA4 and
poor FEV1/FVC, as well as elevated levels of IL-8, for patients with
higher Cif (Fig. 4 D, F, and G). IL-8 and 15-epi LXA4 are strongly
inversely correlated (Fig. 4E). Additionally, in the high-Cif patient
cohort FEV1 values were reduced compared with the low-Cif group
(Fig. S7A). Overall, among subjects with P. aeruginosa infections,
higher Cif levels are associated with worse obstructive lung disease.
Discussion
A major hallmark of the disease cystic fibrosis is vigorous and
persistent pulmonary inflammation, which damages host lung
tissue, eventually causing respiratory failure and death. Chronic
P. aeruginosa infections often accompany robust airway in-
flammatory processes, provoking continuous immune cell in-
filtration into the lung. In the current study, we identified the
epithelial-derived eicosanoid 14,15-EET as an endogenous sub-
strate for the P. aeruginosa virulence factor Cif. We also showed
that the Cif-mediated reduction of 14,15-EET disrupted paracrine
signaling to neutrophils to produce 15-epi LXA4, blocking its
proresolving functions (Fig. S8). Consistent with the Cif-mediated
effect of blocking the generation of proresolving mediators, we
demonstrated that higher Cif levels in the bronchoalveolar lavage
fluid of patients with CF correlated with reduced 15-epi LXA4,
increased inflammatory marker IL-8, and reduced pulmonary
function. Taken together, our results provide evidence for an
unanticipated role of the bacterial epoxide hydrolase Cif in
obstructing normal resolution pathways in the airway and pro-
moting pulmonary inflammation in patients with CF colonized
with P. aeruginosa.
In contrast to the proinflammatory effects of Cif, several
pathogens manipulate lipid mediators to suppress the immune
response and evade detection. Mycobacterium tuberculosis and
Toxoplasma gondii both enhance the generation of lipoxins (21, 22),
whereas the fungal pathogenCandida albicans synthesizes resolvin E1
(23). M. tuberculosis can also inhibit the formation of the proin-
flammatory lipid LTB4, further shifting the host lipid environment
toward an antiinflammatory state (24). P. aeruginosa produces the 15-
lipoxygenase LoxA (25, 26), as well as the phospholipase ExoU (27),
both of which can potentially generate antiinflammatory signals.
However, unlike many airway pathogens, P. aeruginosa survives in a
hyperinflammatory environment, particularly in the context of

























































































































































1 -0.8 -1 -0.6 -0.4 -0.2 0.2 0.4 0.6 0.8 0 
B
Fig. 4. Elevated levels of Cif in CF patient bronchial lavage fluid result in lower
15-epi LXA4 and higher IL-8 concentrations andworsening pulmonary function. (A)
Anti-Cif serum antibodies are generated in adult patients with CF. Sera collected
from a CF and a non-CF cohort were probed for anti-Cif antibodies via ELISA.
Patients with CF have significantly increased levels of anti-Cif serum antibodies
compared with a non-CF cohort. *P ≤ 0.05, Wilcoxon rank-sum test. (B–G) BALF
was obtained from pediatric patients with CF who received bronchoscopy. n = 17.
(B) A visualization of a Pearson correlation matrix depicts positive correlations in
blue and negative correlations in red. Color intensity and the size of the circle are
proportional to the correlation coefficients. Below the correlogram, the scale
shows the correlation coefficients and the corresponding colors. (C) Cif expression
in BALF from patients with CF was determined by Western blot analysis and
binned into “low” and “high” categories. (D) Concentrations of 15-epi LXA4 are
significantly reduced in patients with CF with elevated levels of Cif. CF BALF
samples were lipid extracted and analyzed for 15-epi LXA4 concentrations by
ELISA. *P < 0.05, Wilcoxon rank-sum test. (E) Increased IL-8 concentrations strongly
correlate with lower 15-epi LXA4 concentrations in BALF from patients with CF.
P = 0.0016, Pearson correlation. (F) Patients with CF with elevated Cif have in-
creased IL-8 concentrations in the airways. IL-8 concentrations in CF BALF were
determined by sandwich ELISA and normalized to total protein in each sample.
P = 0.055, Wilcoxon rank-sum test. (G) Patients with CF with high Cif have worse
lung obstruction. Patient FEV1/FVC ratio was measured at time of bronchoscopy,
stratified by high- or low-Cif groups. *P < 0.05, Wilcoxon rank-sum test.









actively manipulates the inflammatory environment in the airway,
other studies have demonstrated that i.v. antibiotic treatments in-
crease LXA4 levels, while decreasing proinflammatory chemokine
concentrations in BALF of patients with CF (28). As a result,
P. aeruginosa may be uniquely poised to exploit both pro- and
antiinflammatory strategies to thwart host defense mechanisms.
It was not expected that 14,15-EET could serve as a host
substrate for P. aeruginosa Cif. Previous crystallization studies
identified Cif as a member of the α/β-hydrolase family of proteins,
with epoxide hydrolase activity focused on small, monosubstituted
substrates (29). Thus, it was surprising to discover that Cif could
accommodate the extended carbon chain of an eicosanoid such as
14,15-EET. Our crystal structure revealed an unexpected rear-
rangement of specific residues that define the boundaries of the
active site. Small-molecule inhibitors were recently reported to drive
conformational changes in an epoxide hydrolase active site (30), but
our study represents an example of a substrate-associated shift in this
class of enzymes. Furthermore, whereas our work shows that Cif
cannot hydrolyze the other EET regioisomers, its active-site flexibility
may enable it to hydrolyze other members of the broad network of
regulatory lipids (31).
Among its multiple antiinflammatory functions (32, 33), 14,15-
EET plays a particularly critical role as a paracrine stimulus for the
production of the proresolving lipid 15-epi LXA4 by neutrophils (19).
In addition to enzymatically targeting 14,15-EET, our study also
demonstrated that Cif indirectly reduced levels of the proresolving
lipid mediator 15-epi LXA4. Previous studies have shown that CF
airways exhibit substantially reduced levels of its epimer LXA4 (15),
although the infection status of the patients was not reported. Our
data provide evidence that the capacity to generate 15-epi LXA4 is
fundamentally intact in the context of CF, yet susceptible to Cif-
mediated reductions when P. aeruginosa is present in the CF airway.
Specifically, the production of 14,15-EET and the associated mod-
ulation of neutrophil behavior were both observed with primary cells
derived from patients with CF. Consistent with this proposal, ele-
vated levels of Cif in BALF from patients with CF correlated with
reduced concentrations of 15-epi LXA4, increased levels of the in-
flammatory cytokine IL-8, and worsened pulmonary function. Our
study suggests that by inhibiting normal host resolution programs, the
secreted P. aeruginosa virulence factor Cif contributes to the char-
acteristic hyperinflammatory environment of the CF airway.
These results have important implications for our understanding
of CF disease pathogenesis. The targeting of the proresolution
14,15-EET/15-epi LXA4 axis represents an unexpected bacterial
virulence strategy. As is demonstrated by decades-long chronic in-
fections in the inflamed lungs of patients with CF, P. aeruginosa
thrives in a hyperinflammatory environment (34). Longitudinal
clinical isolates of P. aeruginosa collected over a decade express cif
(35) and our survey of serum titers from a group of adult subjects
with CF shows that all had generated an immune response to Cif
protein, suggesting that it is widely present in CF airway infections.
Because our results show that Cif enables P. aeruginosa to manip-
ulate the host inflammatory environment, it may play a significant
role in defining the nature of these ongoing infections, which ulti-
mately lead to lung tissue damage and respiratory failure. Cif ho-
mologs have been identified in other airway pathogens, including
Acinetobacter nosocomialis and Burkholderia cepacia (4, 36). As a
result, these bacterial epoxide hydrolases may represent a distinct
class of therapeutic targets in CF and other airway diseases in which
hyperinflammatory responses lead to accelerated tissue damage.
Our observations also suggest additional therapeutic ap-
proaches, as increased Cif levels correlated with more severe ob-
structive lung disease, as measured by FEV1/FVC ratios, in patients
with CF. As increasing FEV1/FVC ratio remains a key therapeutic
objective of clinical therapy, one strategy may be direct replacement
of the absent proresolving lipid mediator. Multiple studies have
demonstrated that exogenous administration of specialized pro-
resolving mediators improves morbidity and mortality outcomes
following infection (11). In particular, the administration of a LXA4
analog in mice challenged intratracheally with P. aeruginosa led to
reduced neutrophil infiltration, weight loss, and bacterial burden,
resulting in overall lessening of disease severity (15). An alternative
strategy may be to inhibit Cif activity with a targeted small-molecule
approach (16, 37). In addition to blocking the enzymatic degrada-
tion of lipid mediators, inhibitors would also block the ability of Cif
to subvert rescue of CFTR by recently approved clinical correctors
(38). Finally, because Cif represents a key link between chronic
infections and the damaging, hyperinflammatory environment pre-
sent in the CF airway, it may serve as a valuable biomarker of airway
disease and treatment options in CF.
Materials and Methods
Protein Expression and in Vitro Hydrolysis Assay.Wild-type Cif protein (Cif-WT)
and Cif-D129S and Cif-E153Qmutants were expressed as described previously
(16, 17, 29). Hydrolysis of the epoxyeicosatrienoic acids by Cif was measured
using a modified adrenochrome assay (36, 39).
Crystallographic Structure of Cif with 14,15-EET. Cif-E153Q protein incubated
with 14,15-EET was crystallized, as described previously (17, 29). Oscillation data
were collected and were processed and scaled with the XDS package (v. December
6, 2010). Phases were calculated by molecular replacement with the Cif-WT struc-
ture [Protein Data Bank (PDB) ID 3KD2] in the Phenix suite (v. 1.10.2055) (40–42).
Standard iterative refinement was performed with Phenix and WinCoot (v. 0.7),
yielding models for two dimers in the asymmetric unit. The ligand was added after
the second round, before the addition of water. We deposited coordinates to the
PDB (PDB ID 5JYC) and used Pymol (www.pymol.org) to render images of chain D.
Epithelial Cell Culture and Bacterial Strains. The immortalized human CF
bronchial epithelial cell line CFBE41o− (referred to here as CFBE cells) was seeded
on 0.4-μM polyester Transwell filters (Corning) coated with collagen and fibro-
nectin and grown at air–liquid interface for at least 7–10 d, as previously described
(43). Primary human CF AECs (CF HBEs) acquired from the University of Pittsburgh
Airway Cell and Tissue Core were cultured from explanted lungs of patients with
CF, using an Institutional Review Board approved protocol at the University of
Pittsburgh (IRB no. 11070367) (44). P. aeruginosa strains PA14 and PA14Δcif were
gifts from George O’Toole, Geisel School of Medicine at Dartmouth (7, 45).
Quantification of 14,15-EET. Polarized CFBE cells were treated with TNFα (R&D
Systems) for 24 h prior to treatment with either Cif-WT or PA14 [multiplicity of
infection (MOI) = 25]. Apical supernatants were collected in methanol, layered
with N2, and solid-phase lipid extracted using C18 Sep-Pak cartridges (Waters) as
previously described (19, 46). The 14,15-EET concentrations were quantified by
ELISA (Detroit R&D) using prostaglandin B2 (100 ng) as an internal standard and
monitored by HPLC to control for variances in extraction recovery. The 14,15-
EET concentrations in apical supernatants were confirmed by liquid chroma-
tography mass spectrometry, using previously described techniques (47, 48).
Neutrophil Isolation, 15-epi LXA4 Quantification, and Transepithelial Migration.
Neutrophils were obtained by venipuncture from volunteers who had given
written informed consent according to a protocol approved by the University of
Pittsburgh IRB Committee (IRB no. 14070447). Neutrophils isolated as previously
described (49) were incubated with 14,15-EET (Cayman Chemical). In some con-
ditions 14,15-EET was previously incubated with Cif-WT or Cif-D129S before
neutrophil treatment. All reactions were collected in methanol and solid-phase
lipid extracted, and 15-epi LXA4 concentrations were determined by ELISA (Neo-
gen) (50). For neutrophil–AEC coculture experiments, CFBE cells were treated with
TNFα for 24 h and exposed to Cif before the addition of neutrophils. For trans-
epithelial neutrophil migration, CFBE cells were seeded on inverted 3-μM pore
polycarbonate Transwell filters (51). Calcein AM (Life Technologies)-labeled neu-
trophils were treated with 15-epi LXA4 or 14,15-EET in the presence of Cif-WT or
Cif-D129S and applied to the basolateral side of CFBE cells. IL-8 (100 pg/mL) ap-
plied to the apical compartment stimulated neutrophil transepithelial migration
(20), which was measured by Calcein AM fluorescence following a 2-h incubation.
Antibody Detection in Human Sera. Deidentified human serum samples were
obtained from the Translational Research Core at Geisel School of Medicine,
in accordance with the approved IRB protocol (IRB no. 22781). An indirect
ELISA, with purified Cif-WT protein as bait, was developed to detect human
antibodies against Cif from a 1:5,000 dilution of the serum.
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Analysis of BALF from Subjects with CF. BALF was collected prospectively over
time in a pediatric population followed for management of CF at Children’s
Hospital of Pittsburgh, in accordance with a protocol approved by the University
of Pittsburgh IRB Committee (IRB no. 504067). ELISAs were used to determine 15-
epi LXA4 (Neogen) and IL-8 (R&D Systems) concentrations in BALF of patients
with CF. Cif protein quantification was determined by Western blot analysis de-
tected by Cif-specific rabbit antisera (Cocalico Biologicals). Cif and IL-8 values were
normalized and expressed per milligram of total BALF protein. Pulmonary func-
tion testing (PFT) was performed on all patients as part of their CF management
and the most recent PFT data in relation to the bronchoscopy were collected.
Statistics. Experimental differences for in vitro assays were evaluated for sta-
tistical significance by one-way analysis of variance (ANOVA) with a Tukey’s post
hoc test (GraphPad 6.0). For the human studies, a Pearson correlation matrix was
created using the cor package in R from measurements of Cif, 15-epi LXA4, IL8,
and spirometry values for the 16 patients for whom a complete set of values was
available. The corrplot package in R was used to visualize the results. Significance
was determined using the nonparametricWilcoxon rank-sum test (GraphPad 6.0)
for serum antibody titers and differences between high and low Cif cohorts.
Additional methods can be found in SI Materials and Methods.
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